BioSpace News Archive

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced data from initial feasibility studies of its novel visceral lesion applicator (VLA) have been accepted to be presented at the Annual Meeting of the Society of Interventional Oncology in New Orleans from January 30 - February 3, 2020.

Cognita Labs, a respiratory technologies company, announced U.S. Food and Drug Administration (FDA) clearance for CapMedic, world’s first interactive digital inhaler sensor for asthma, Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary conditions.

The Preeclampsia Foundation announced that Nicole Purnell, program manager of MoMMA’s Voices, has been selected to serve on the National Quality Forum’s Maternal Morbidity and Mortality Committee as a patient advocate.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”).

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate futibatinib (TAS-120), a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR).

Patients with Lewy body dementia may be eligible for a study of a treatment that was found to be effective in Alzheimer’s disease, according to results of ongoing studies.

Castellum, Inc. (OTC: ONOV) announces Jim Enicks, Colonel, U.S. Army Retired, has agreed to become CEO of the Company’s subsidiary, Corvus Consulting.

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4

The American Cancer Society and Pfizer have approved grants totaling more than $2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis.

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans